Comments
Loading...
Cullinan Therapeutics (NASDAQ:CGEM) Stock, Earnings Estimates, EPS, And Revenue
Cullinan Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Nov 7
EPS
$-0.690
Quarterly Revenue
$0K
Annual Revenue
(as of Sep 30)
(as of Sep 30)
–
Analyze the earnings history of Cullinan Therapeutics using advanced sorting and filters.
Data brought to you by Benzinga APIs
Cullinan Therapeutics (CGEM) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-11-07 | $-0.69 | $-0.81 | 14.8 % |
| Jun 2024 | 2024-08-08 | $-0.75 | $-0.73 | -2.74 % |
| Mar 2024 | 2024-05-15 | $-0.86 | $-0.95 | 9.47 % |
| Dec 2023 | 2024-03-14 | $-0.54 | $-0.96 | 43.8 % |
Cullinan Therapeutics (CGEM) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
FAQ
When is Cullinan Therapeutics (NASDAQ:CGEM) reporting earnings?
Cullinan Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 7, 2024 for Q3.
What were the latest earnings per share (EPS) for Cullinan Therapeutics (NASDAQ:CGEM)?
Cullinan Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 7, 2024 for Q3 and the Actual EPS was $-0.69, which beat the estimate of $-0.81.
What were Cullinan Therapeutics’s (NASDAQ:CGEM) revenues?
Cullinan Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 7, 2024 for Q3 and the Actual EPS was {{actualEPS}}, which hit the estimate of {{estEPS}}.
Browse earnings estimates, EPS, and revenue on all stocks.